期刊文献+

骨髓增殖性肿瘤患者并发急性冠脉综合征相关因素分析 被引量:3

The association factors of acute coronary syndrome in patients with myeloproliferative neoplasms
下载PDF
导出
摘要 目的通过病例总结,分析骨髓增殖性肿瘤(MPN)患者中急性冠脉综合征(ACS)病例的特征,探讨其相关因素。方法选择2004年至2014年于北京协和医院住院并确诊MPN的125例患者,收集其人口学资料(年龄,性别)、心血管病危险因素(吸烟、高血压病、高脂血症和糖尿病)等信息,分析ACS病例的基本特征,通过Spearman相关性分析寻找ACS的可能相关因素。结果共7例ACS病例(发病率为5.6%);ACS组与非ACS组相比,既往冠心病史、血红蛋白(HGB)(P<0.001)和白细胞(WBC)(P<0.05)3个项目存在显著性差异;分析发现ACS与既往冠心病史、WBC计数呈显著正相关(P<0.01)。结论 ACS是MPN人群主要血栓并发症之一;既往冠心病史,外周血白细胞增多可能与MPN人群的ACS相关。 Objective Through summarizing cases, analyze the characteristics of acute coronary syndrome patients in myeloproliferative neoplasms (MPN) population, and investigate the association factors of acute coronary syn- drome (ACS). Methods In total 125 cases of hospitalized patients diagnosed of MPN in Peking Union Medical College Hospital in 2004 -2014 were included in this study. The information of demographic data (age, gender), cardiovascular risk factors (smoking, hypertension, hyperlipidemia, diabetes), previous history of thrombosis, previous history of coronary artery disease, previous history of other peripheral vascular disease, previous hydroxyurea or anti-platelet therapy, and laboratory parameters (complete blood count, coagulation functions) was collected and further analyzed for basic characteristics of ACS cases; Spearman correlation analysis was applied to explore association factors of acute coronary syndromes. Results A total of 7 cases developed ACS (incidence 5.6% ). Between ACS and non-ACS patients, significant difference existed in previous history of coronary artery disease ( 18.6% vs 85.7%, P 〈0. 001, hemoglobin level ( 141 ±45 vs 171 ±13, P 〈0. 001 ) and leukocyte count (10. 76 ± 8.09 vs 17.88 ± 8.79, P 〈 0.05). Spearman analysis found significant positive correlations between ACS and previous history of coronary artery disease and leukocyte count (correlation coefficients were 0. 361,0. 271, respectively; P 〈 0. 05). Conclusion ACS is one of the major thrombosis complications in MPN population. Previous history of coronary artery disease and leukocytosis probably associated with ACS in MPN population.
出处 《基础医学与临床》 CSCD 2015年第4期514-517,共4页 Basic and Clinical Medicine
关键词 骨髓增殖性肿瘤 急性冠脉综合征 myeloproliferative neoplasms acute coronary syndrome
  • 相关文献

参考文献15

  • 1Campbell PJ,Green AR. The myeloproliferative disorders[J]. N Engl J Med, 2006, 355: 2452-2466.
  • 2Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagiccomplications of myeloproliferative disorders [ J ]. BloodRev, 2010, 24:227-232.
  • 3Vannucchi AM. Insights into the pathogenesis and manage-ment of thrombosis in polycythemia vera and essentialthrombocythemia [ J ]. Intern Emerg Med, 2010,5:177-184.
  • 4Landolfi R, Di Gennaro L, Falanga A, Thrombosis in my-eloproliferative disorders : pathogenetic facts and speculation[J]. Leukemia, 2008,22: 2020-2028.
  • 5Italiano G. Polycythemia vera: the natural history of 1213patients followed for 20 years. Gruppo Italiano Studio Po-licitemia[ J]. Ann Intern Med, 1995, 123: 656-664.
  • 6Harrison CN, Campbell PJ, Buck G, et al. Hydroxyureacompared with anagrelide in high-risk essential thrombocy-themia[J]. N Engl J Med, 2005, 353: 33-45.
  • 7Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosisas a major thrombotic risk factor in patients with polycythe-mia vera[J]. Blood,2007, 109: 2446-2452.
  • 8Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocyto-sis and risk stratification assessment in essential thrombocy-themia[J]. J Clin Oncol, 2008, 26: 2732-2736.
  • 9Landolfi R, Di Gennaro L, Falanga A. Thrombosis in my-eloproliferative disorders: pathogenetic facts and speculation[J]. Leukemia, 2008, 22: 2020-2028.
  • 10买买提力·依马木,王晓敏,李燕,安利.原发性血小板增多症与血栓形成的相关性研究[J].国际输血及血液学杂志,2013,36(5):385-388. 被引量:4

二级参考文献11

  • 1Kralovics R, Passamonti F, Buser AS, et a|. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005, 352(17)1779-1790.
  • 2Palandri F, Polverelli N, Catani I., et al. Impact of leukocytosison thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol, 2011, 90(8) :933-938.
  • 3Tefferi A, Vardiman JW. myeloproliferative neoplasm Organization criteria and po Leukemia, 2008, 22(1) :14 2 Classification and diagnosis of s : the 2008 World Health int of-care diagnostic algorithms. 2.
  • 4Levine LR, Gilliland DG. Myeloproliferative disorders. Blood, 2008(112) :2190-2197.
  • 5Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol, 2012, 87(3):285-293.
  • 6Alessandra C, Guido F, Elisabetta A, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood, 2008, 112(8) :3135-3137.
  • 7Elliott MA, Tefferi A. Thrombosis and haemorrhage in polyeythemia vera and essential thrombocythaemia. Br J Hematology, 2004, 128(2):275-290.
  • 8Smith CA, Fan G. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms. Hum Pathol, 2008,39(6) :795-810.
  • 9Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JA K2 mutation status. Blood, 2007, 109(6) :2310 2313.
  • 10Campell PJ, Linda MS, Georgina B, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V61?F mutation status: A prospective study. Lancet, 2005, 366 (9501)1945 1953.

共引文献3

同被引文献11

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部